NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $31.00 price target on the stock.

Several other equities research analysts have also recently issued reports on the company. Ascendiant Capital Markets lifted their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a report on Friday.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ NRXP traded down $0.28 during midday trading on Monday, hitting $2.07. 202,980 shares of the stock traded hands, compared to its average volume of 450,140. The firm has a 50-day moving average of $3.02 and a two-hundred day moving average of $2.02. The firm has a market capitalization of $35.02 million, a P/E ratio of -0.96 and a beta of 1.22. NRx Pharmaceuticals has a one year low of $1.10 and a one year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10). Equities analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling at NRx Pharmaceuticals

In other news, Chairman Jonathan C. Javitt purchased 40,000 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average price of $1.17 per share, for a total transaction of $46,800.00. Following the completion of the acquisition, the chairman now owns 84,634 shares of the company’s stock, valued at approximately $99,021.78. This trade represents a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 19.00% of the company’s stock.

Hedge Funds Weigh In On NRx Pharmaceuticals

Large investors have recently bought and sold shares of the business. Townsquare Capital LLC acquired a new position in shares of NRx Pharmaceuticals during the third quarter worth $25,000. Sassicaia Capital Advisers LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth $33,000. Squarepoint Ops LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth $56,000. Millennium Management LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth $61,000. Finally, Anson Funds Management LP acquired a new position in shares of NRx Pharmaceuticals during the third quarter worth $241,000. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.